Recursion Pharmaceuticals, Inc. (RXRX)
Nasdaq: RXRX · Biological Products, (No Diagnostic Substances) · Salt Lake City, UT · filing with the SEC since 2014
Filings
236 filings since 2017 beside 749 insider forms · Large accelerated filer · read from EDGAR on Nov 13, 2026Due nextLarge accelerated filer
10-K
Annual report for the fiscal year ending Dec 31, 2026Large accelerated filers have 60 days after the fiscal year ends.
by Mar 1, 2027
10-Q
Quarterly report for the quarter ending Mar 31, 2027Large accelerated filers have 40 days after the quarter ends; quarter ends are taken to the month end.
by May 10, 2027
A deadline is the latest date the SEC's rules allow for its filer category. It is not a forecast of the day the company files. Last time, the results release (8-K item 2.02) came 33 days after the quarter ended. The proxy statement was last filed Apr 30, 2026.
Filings a yearinsider forms included
1298111241265115151
2026 counts to Nov 13, 2026.
Officer or director change (8-K item 5.02): 11 times in the last 36 months, the newest Nov 2, 2026.Auditor change (8-K item 4.01): 2 times in the last 36 months, the newest May 24, 2024.SEC letters: 3 in the last 36 months, the newest Jun 13, 2024.
Insider forms (3, 4, 5 and 144) are counted each year but not listed here; the people and their trades are on the Ownership tab.
FiledFormWhat it is, in plain wordsPeriodAsk
Nov 2, 2026
8-K items 2.02, 5.02, 7.01, 9.01
Results released; Officer or director change; Investor disclosure (Regulation FD) · Current report
Oct 31, 2026
Oct 15, 2026
8-K items 1.01, 2.02, 7.01, 8.01, 9.01
Major agreement signed; Results released; Investor disclosure (Regulation FD); Other event · Current report
Aug 5, 2026
8-K items 2.02, 7.01, 9.01
Results released; Investor disclosure (Regulation FD) · Current report
May 6, 2026
8-K items 2.02, 7.01, 9.01
Results released; Investor disclosure (Regulation FD) · Current report
Apr 30, 2026
8-K items 5.02, 7.01, 9.01
Officer or director change; Investor disclosure (Regulation FD) · Current report
Apr 28, 2026
Mar 25, 2026
8-K items 5.02, 7.01, 9.01
Officer or director change; Investor disclosure (Regulation FD) · Current report
Feb 25, 2026
8-K items 2.02, 7.01, 9.01
Results released; Investor disclosure (Regulation FD) · Current report
Nov 5, 2025
8-K items 2.02, 5.02, 7.01, 9.01
Results released; Officer or director change; Investor disclosure (Regulation FD) · Current report
Nov 4, 2025
Aug 29, 2025
8-K/A items 3.02, 8.01, 9.01
Shares sold without registration; Other event · Current report, amended
Jul 8, 2025
40 of 236 shown
Every row opens the filing on EDGAR. The plain words are the site's own for each form and each 8-K item; the complete history, insider forms included, is on EDGAR.